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Abstract Body weight is a highly heritable trait across
species. In humans, genetic variation plays a major role in
determining the inter-individual differences in suscepti-
bility or resistance to environmental factors which influ-
ence energy intake and expenditure. In this review, I
discuss how genetic studies have contributed to our
understanding of the central pathways that govern energy
homeostasis. The study of individuals harboring highly
penetrant genetic variants that disrupt the leptin–melano-
cortin pathway has informed our understanding of the
physiological pathways involved in mammalian energy
homeostasis.
Introduction
In humans, there is a strong evidence that within a popu-
lation the variance in body weight and in body mass index
(BMI; weight in kg/height in meters squared) is strongly
influenced by genetic factors (Maes et al. 1997), with
family, twin and adoption studies yielding heritability
estimates that range between 40 and 70 % (Stunkard et al.
1986, 1990; Sorensen et al. 1989). In experimental over-
feeding studies, Bouchard and colleagues showed that
weight gain induced by overfeeding identical male twin
pairs by 10 % of their energy requirements differed across
sets of twins but was similar between members of a twin
pair (Bouchard et al. 1990). Similarly, the response to
negative energy balance was also heritable when the same
individuals were calorically restricted (Bouchard et al.
1996). Given the high heritability of body weight, genetic
approaches can be a useful tool with which to dissect the
mechanisms involved in energy homeostasis. A number of
contrasting experimental approaches have been used to
identify human obesity-associated genes.
Finding common genetic variants that are associated
with increased risk of obesity
Genome-wide association studies (GWASs) are based on
the premise that the heritability of common diseases is
made up of a large number of common variants [minor
allele frequency (MAF) of more than 5 %]. To this end, the
use of high throughput arrays has facilitated the genotyping
of thousands of common variants covering more than 75 %
of the genome in large population-based cohorts on whom
body mass index data is available. The first GWAS-derived
loci detected were intronic variants in the FTO (fat mass
and obesity-associated) gene (Frayling et al. 2007; Dina
et al. 2007) and variants approximately 200 kb downstream
of MC4R (Loos et al. 2008). To date, more than 50 genetic
loci relevant for body weight regulation have been identi-
fied by GWAS approaches (Loos 2012). While GWAS-
associated signals are often identified by the name of the
nearest gene, there is little evidence to suggest that varia-
tion in these specific genes explains the association signal.
Furthermore, many of the signals identified to date map to
non-coding regions of the genome so their functional sig-
nificance needs to be determined. The strongest association
with BMI in individuals of Caucasian origin has consis-
tently been found with SNPs in the first intron of FTO.
Similar observations have been made in other ethnic
groups (Zhang et al. 2008; Li et al. 2008). Homozygotes for
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the risk allele of the most common SNP in FTO are 3–4 kg
heavier than those without the risk allele and have a 1.67-
fold increased risk of obesity (Frayling 2007). Several
human studies have demonstrated an association between
SNPs in FTO and energy intake rather than energy
expenditure (Wardle et al. 2008). FTO is expressed in the
hypothalamus, and its expression has been suggested to be
nutritionally regulated by some (although not all) groups
(Gerken et al. 2007; Stratigopoulos et al. 2008). Fto-null
mice are small with increased energy expenditure (Fischer
et al. 2009), although the effect is negligible when using
the linear regression method to correct for differences in
lean mass (McMurray et al. 2013). In contrast, mice
overexpressing Fto are obese (Church et al. 2010). Genes
within the region of interest are evaluated as potential
candidates for causing the association such as RPGRIP1L
(Stratigopoulos et al. 2011, 2014), but the association may
also arise due to long-range genetic interactions as evi-
denced recently by work which suggests that the nearby
gene IRX3 may be important (Smemo et al. 2014).
Cumulatively, the common variants identified in
GWASs are characterized by modest effect sizes (per-allele
odds ratios between 1.2 and 1.5), and the proportion of
variability explained by GWAS-identified loci to date
remains relatively modest (\5 %). Studies in childhood
onset obesity and in severely obese children and adults
have shown that there is some overlap between the com-
mon variants that contribute to early-onset and adult-onset
weight gain (Wheeler et al. 2013), but also that both these
approaches can identify novel variants that are not found in
adult populations (Bradfield et al. 2012). Differences in
genetic architecture as well as in environmental con-
founders may explain some of the discordance between
different GWAS studies. While meta-analyses of even
larger datasets are underway, there is a growing consensus
in the study of common complex diseases that additional
common variants are unlikely to explain the missing heri-
tability underlying traits such as BMI or obesity. There is
the possibility that the heritability of obesity-related phe-
notypes may have been overestimated, as the effects of the
shared environment and, in the case of twins, the shared in
utero environment, are difficult to separate from inherited
influences.
Candidate gene studies
Candidate gene studies based on the molecules known to
cause severe obesity in experimental animals have shown
that these genes also contribute to childhood onset human
obesity. The foundation for this work was laid by elegant
physiological studies showing that the regulation of body
weight is a homeostatic process (Friedman 2000), which
has been demonstrated by lesioning studies to be regulated
at the level of the hypothalamus. Parabiosis experiments in
inbred strains of mice with severe obesity, such as ob/ob
and db/db, suggested the existence of a circulating factor
that regulates weight which was missing in ob/ob mice and
to which db/db were resistant (Coleman and Hummel
1969). The identification of this hormone, leptin, through
positional cloning of the ob gene, and the finding that this
was mutated in severely obese ob/ob mice (Zhang et al.
1994) paved the way for the molecular and physiological
circuits controlling energy homeostasis to be dissected.
Leptin is a 16-kDa hormone whose circulating levels cor-
relate closely with fat mass. Many of the physiological
effects of leptin are mediated through the central nervous
system, particularly the hypothalamus, which is the site of
the highest mRNA expression of the long signaling isoform
of the leptin receptor. Leptin stimulates pro-opiomelano-
cortin (POMC) expressing primary neurons in the arcuate
nucleus of the hypothalamus. POMC is post-translationally
processed to yield the melanocortin peptides, which are
agonists at melanocortin 3 and 4 receptors. In addition,
leptin inhibits neurons expressing the melanocortin antag-
onist Agouti-related protein and neuropeptide Y (NPY);
NPY can suppress the expression of POMC. These primary
leptin-responsive neurons project to second-order neurons
expressing the melanocortin 4 receptor (MC4R). Targeted
genetic disruption of MC4R in mice leads to increased food
intake and increased lean mass and linear growth (Huszar
et al. 1997). These hypothalamic pathways interact with
other brain centers to coordinate energy intake and energy
expenditure (Cummings and Schwartz 2003).
Insights from genetics—leptin signaling
We and others have demonstrated that human obesity can
result from a multiplicity of defects in the leptin–melano-
cortin pathway (Fig. 1). Generally these disorders are rare,
being found in 1–5 % of patients with severe obesity (own
observations). Individuals with homozygous loss-of-func-
tion mutations in the genes encoding leptin and the leptin
receptor have a normal birthweight but exhibit rapid weight
gain in the first few months of life resulting in severe
obesity (Montague et al. 1997; Farooqi et al. 2002).
Characteristic features are an intense drive to eat (hyper-
phagia) as well as impaired satiety with food-seeking
behavior soon after the end of a meal. Recombinant human
leptin injections are effective in these individuals leading to
normalization of hyperphagia, enhanced satiety, and
weight loss (Farooqi et al. 1999). Leptin is also involved in
mediating food reward. In rodents, leptin receptors are
expressed in the mesolimbic brain regions which mediate
the rewarding properties of food and drugs (Barge-
378 S. Farooqi: Genetic strategies
123
Schaapveld et al. 2011). Leptin administration decreases
the firing threshold of dopaminergic neurons within this
system, while long-term RNAi-mediated knockdown of
Lepr in the ventral tegmental area has been shown to
increase food intake and sensitivity to highly palatable food
(Hommel et al. 2006). In leptin-deficient humans, images
of food (compared to non-food images) are associated with
a marked increase in neuronal activation in the ventral
striatum imaged using functional MRI. This response was
normalized by 7 days of leptin treatment (Farooqi et al.
2007a) before significant weight loss consistent with the
view that activation in the ventral striatum does not directly
encode the ‘‘liking’’ but rather the motivational salience, or
‘‘wanting,’’ of food.
In leptin-deficient children and adults, basal metabolic
rate, total energy expenditure, and free-living energy
expenditure are appropriate for body composition (Farooqi
et al. 2007c). Ravussin and colleagues showed that before
weight loss, leptin-deficient adults and matched controls
had similar energy expenditures. However, after weight
loss, controls had energy expenditures lower than expected
for their new weight and body composition (Galgani et al.
2010). This is a well-known phenomenon, often called the
metabolic adaptation to weight loss, i.e., a decrease in
metabolic rate beyond that expected on the basis of the
decrease in fat-free mass and fat mass. Therefore, the
absence of this change in energy expenditure in some
leptin-deficient adults is consistent with an effect of leptin
on energy expenditure.
Body composition measurements show that leptin defi-
ciency is characterized by the preferential deposition of fat
mass (compared with lean mass), and weight loss leads to a
preferential loss of fat mass. In rodents, leptin stimulates
fatty acid oxidation in skeletal muscle via the stimulation
of AMP kinase activity (Minokoshi et al. 2002). In leptin-
deficient humans, impaired fat oxidation has been dem-
onstrated by chamber calorimetry (Galgani et al. 2010).
Ozata et al. (1999) have reported abnormalities of sym-
pathetic nerve function in leptin-deficient adults consistent
with defects in the efferent sympathetic limb of thermo-
genesis. Evidence from rodents and humans suggests that
leptin is necessary for the normal biosynthesis and secre-
tion of thyrotropin-releasing hormone and that complete
leptin deficiency is associated with a moderate degree of
hypothalamic hypothyroidism characterized by low free
thyroxine and high serum thyroid-stimulating hormone,
which is bio-inactive (Gibson et al. 2004).
Insights from genetics—melanocortinergic circuits
Leptin signaling modulates energy balance through a
combination of melanocortin-dependent and -independent
pathways. In humans, null mutations in POMC lead to
hyperphagia, early-onset obesity, isolated adrenocortico-
tropin (ACTH) deficiency, and hypopigmentation of skin
and hair (Coll et al. 2007). Heterozygous null mutations in
POMC and loss-of-function mutations in a- and b-mela-
nocyte-stimulating hormone (a- and b-MSH) significantly
increase obesity risk but are not invariably associated with
obesity (Coll et al. 2004).
Prohormone convertase 1 (PCSK1) is an enzyme
involved in the cleavage of POMC into ACTH, which is
then further cleaved to make a-MSH by carboxypeptidase
E. Humans lacking PCSK1 are severely obese and have
glucocorticoid deficiency, hypogonadotropic hypogonad-
ism, and postprandial hypoglycemia, which occurs as a
result of impaired processing of proinsulin to insulin by
PCSK1 (Farooqi et al. 2007b). Elevated plasma levels of
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proinsulin and 32–33 split proinsulin in the context of low
levels of mature insulin provide the basis for a diagnostic
test for this disorder (Jackson et al. 1997).
We and others have reported that mutations in MC4R
are found in 5–6 % of patients with severe early-onset
obesity (Farooqi et al. 2003; Stutzmann et al. 2008) and at a
frequency of approximately 1/1,000 in the general UK
population, making this one of the most common human
genetic diseases. Functionally significant MC4R mutations
are inherited in a co-dominant manner, with variable pen-
etrance and expression in heterozygous carriers. Most
naturally occurring disease-causing MC4R mutations dis-
rupt normal expression and trafficking of the receptor to the
cell surface (Vaisse et al. 2000). The mechanism of GPCR
dysfunction has potential interest, as we have shown that
pharmacological chaperones can increase the cell surface
expression and signaling of mutant GPCRs. We have pre-
viously characterized human MC4R deficiency and repor-
ted hyperphagia, increased lean mass, and increased linear
growth and demonstrated a genotype-phenotype correla-
tion with the degree of receptor dysfunction in vitro pre-
dicting all aspects of the phenotype, including ad libitum
energy intake (Farooqi et al. 2007c).
We have shown that both increase and decrease in
central melanocortin signaling influence blood pressure in
humans and that the effects are not explained by changes in
circulating insulin levels or insulin sensitivity (Greenfield
et al., 2009). MC4R-deficient patients with long-standing
decreases in melanocortinergic tone have a lower preva-
lence of hypertension and lower systolic and diastolic
blood pressures. These changes are associated with reduced
sympathetic nervous system activity. Also, administration
of a melanocortin receptor agonist in obese volunteers
increases blood pressure. Thus, central melanocortin sig-
naling appears to play an important role in the regulation of
blood pressure and its coupling to changes in weight. With
weight gain, leptin levels increase, thereby increasing sig-
naling through MC4R. As MC4R neurons synapse with
preganglionic sympathetic neurons which regulate vascular
tone, increased signaling through MC4R can lead to an
increase in blood pressure. This mechanism explains why
reduced melanocortin signaling in people with loss-of-
function MC4R mutations, may be associated with reduced
blood pressure.
Insights from genetics—molecules downstream
of MC4R and other mechanisms
Several lines of evidence suggest that Brain-derived neu-
rotrophic factor (BDNF), a nerve growth factor which
activates signaling by the tyrosine kinase receptor tropo-
mycin-related kinase B (TrkB), and SIM1 may lie
downstream of MC4R signaling in the paraventricular
nucleus. Haploinsufficient mice and mice in which BDNF
has been deleted postnatally are obese with hyperphagia
and hyperactivity; this unusual combination of phenotypes
is also seen in individuals with genetic disruption of BDNF
or its receptor TrkB (Gray et al. 2006; Yeo et al. 2004).
Single minded 1 (SIM1) is a transcription factor involved
in the development of the paraventricular and supraoptic
nuclei of the hypothalamus. A de novo balanced transloca-
tion between chromosomes 1p22.1 and 6q16.2, which dis-
rupts SIM1 (Holder et al. 2000), and missense mutations in
SIM1 cause severe obesity and a variable phenotype of
developmental delay (Ramachandrappa et al. 2013). The
transcriptional targets of SIM1 are unknown, but one
potential target is the neuropeptide oxytocin. Oxytocin
mRNA levels are reduced in line with Sim1 gene dosage in
mouse models of Sim1 deficiency. The hyperphagia of Sim1-
haploinsufficient animals is ameliorated by oxytocin
administration and accentuated by the administration of
oxytocin receptor antagonists (Kublaoui et al. 2008).
Recent studies have suggested a connection between
ciliary function and leptin signaling (Seo et al. 2009).
Conditional postnatal knockout of proteins involved in
intraflagellar transport in mice results in hyperphagia and
obesity. This phenotype is recapitulated when the loss of
cilia is limited to neurons and when it is specifically tar-
geted to POMC neurons. As several human obesity disor-
ders disrupt genes involved in ciliary function (e.g.,
Alstro¨m syndrome and Bardet-Beidl syndrome) (Tobin
and Beales 2007), the role of cilia in key neuronal popu-
lations involved in energy homeostasis is likely to be the
subject of much future research.
Finding the missing heritability in human obesity
Next-generation sequencing technologies are currently
being used to undertake CNV analysis (Walters et al. 2010)
and whole exome sequencing in obese cohorts and popu-
lations (Gill et al. 2014). The aim of these studies is to find
low-frequency/rare genetic variants, but assessing the
potential pathogenicity of those variants remains a major
challenge. While statistical and computational methods are
continually emerging to address these challenges, as with
other hypothesis-free genetic approaches the technique is
ultimately only as powerful as the genetic material being
interrogated. Initial methodological approaches have ten-
ded toward sequencing related individuals, or sequencing
individuals at opposing extremes of the phenotypic spec-
trum. The contribution of epigenetic modulation and of
non-coding genetic variation to the missing heritability of
obesity remains to be explored.
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